Gero Kramer
Vienna General Hospital · 312 works · 8,563 citations · h-index 45
Top works
- Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017
- Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer
- Is Benign Prostatic Hyperplasia (BPH) an Immune Inflammatory Disease?
- High‐grade prostate cancer is associated with low serum testosterone levels
- Docetaxel induces apoptosis in hormone refractory prostate carcinomas during multiple treatment cycles
- The Controversial Relationship Between Benign Prostatic Hyperplasia and Prostate Cancer: The Role of Inflammation
- Differentiation between Cell Death Modes Using Measurements of Different Soluble Forms of Extracellular Cytokeratin 18
- Increased expression of lymphocyte‐derived cytokines in benign hyperplastic prostate tissue, identification of the producing cell types, and effect of differentially expressed cytokines on stromal cell proliferation
- Cytokine Expression Pattern in Benign Prostatic Hyperplasia Infiltrating T Cells and Impact of Lymphocytic Infiltration on Cytokine mRNA Profile in Prostatic Tissue
- Unenhanced Multi–Detector Row CT in Patients Suspected of Having Urinary Stone Disease: Effect of Section Width on Diagnosis
- Hypothyroidism in patients with renal cell carcinoma
- High Expression of a CD38-Like Molecule in Normal Prostatic Epithelium and its Differential Loss in Benign and Malignant Disease
- Urolithiasis in allograft kidneys
- Phenotype and Function of Peripheral and Prostatic Lymphocytes in Patients with Benign Prostatic Hyperplasia
- Role of bacteria in the development of kidney stones
- Could inflammation be a key component in the progression of benign prostatic hyperplasia?
- 68Ga-PSMA 11 ligand PET imaging in patients with biochemical recurrence after radical prostatectomy – diagnostic performance and impact on therapeutic decision-making
- Response assessment using 68Ga-PSMA ligand PET in patients undergoing 177Lu-PSMA radioligand therapy for metastatic castration-resistant prostate cancer
- PSMA Ligand PET/MRI for Primary Prostate Cancer: Staging Performance and Clinical Impact
- Management of patients with advanced prostate cancer—metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022